Medtronic's Abre venous stent receives FDA approval

• Medtronic (MDT -2.5%) has received U.S. FDA approval for the Abre™ venous self-expanding stent system for the patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.
• The FDA approval is based on 12-month results from the ABRE clinical study, presented at the 2020 Charing Cross Symposium.
• The study also met its 12-month primary effectiveness endpoint with an overall primary patency rate of 88% (162/184).
• Despite the challenging patient population, no stent fractures and no stent migrations were reported in the study.
• https://seekingalpha.com/news/3625790-medtronics-abre-venous-stent-receives-fda-approval